Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 1/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.56 |
| ▸ | HTR3B | O95264 | 5/20 | 0.56 |
| ▸ | HTR3A | P46098 | 5/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1079670 | 1.00 | RAD51 (0.58) | RAD51HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7401133 | 0.83 | PTPN1 (0.54) | RAD51HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7400768 | 0.81 | HTR3E (0.57) | RAD51HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL13082235 | 0.81 | RAD51 (0.51) | RAD51HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8569855 | 0.79 | PTPN1 (0.61) | RAD51HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7400933 | 0.77 | RAD51 (0.61) | RAD51HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3789425 | 0.77 | KDM4E (0.61) | RAD51HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL27077503 | 0.75 | PTPN1 (0.43) | RAD51HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL20816302 | 0.74 | RAD51 (1.00) | RAD51HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL27693898 | 0.73 | HTR3E (0.55) | RAD51HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275646-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2010-05-13 | — | — | US | disclosed |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
| US-20060235034-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275646-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | VEGFA, TEK, LIPG | RAD51 1982/4885HTR3E 1190/4885HTR3B 1724/4885 |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | VEGFA, TEK, MCL1 | RAD51 1879/4885HTR3E 1388/4885HTR3B 2016/4885 |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | VEGFA, TEK, MCL1 | RAD51 1879/4885HTR3E 1388/4885HTR3B 2016/4885 |
| US-20060235034-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | VEGFA, TEK, MCL1 | RAD51 1879/4885HTR3E 1388/4885HTR3B 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.